Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Top Cited Papers
- 10 February 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (6), 533-540
- https://doi.org/10.1056/NEJMoa2034545
Abstract
Background The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. Methods We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time. Results A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P=0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status. Conclusions The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.) In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.Funding Information
- U.K. Government
This publication has 28 references indexed in Scilit:
- Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patientsJournal of Infection, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNature Medicine, 2020
- Antibody testing for COVID-19: A report from the National COVID Scientific Advisory PanelWellcome Open Research, 2020
- Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent IndividualsPublished by Cold Spring Harbor Laboratory ,2020
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort studyThe Lancet Infectious Diseases, 2020
- Consistent Detection of 2019 Novel Coronavirus in SalivaClinical Infectious Diseases, 2020
- The investigation of interferences in immunoassayClinical Biochemistry, 2017
- Vaccines: Correlates of Vaccine‐Induced ImmunityClinical Infectious Diseases, 2008
- Duration of RT-PCR positivity in severe acute respiratory syndromeEuropean Respiratory Journal, 2005